既往消融治疗后肺立体定向放射治疗:单一机构病例系列。

Pub Date : 2018-12-21 eCollection Date: 2018-11-01 DOI:10.2217/lmt-2018-0012

Rodney E Wegner, Nissar Ahmed, Shaakir Hasan, Lana Y Schumacher, Athanasios Colonias

{"title":"既往消融治疗后肺立体定向放射治疗:单一机构病例系列。","authors":"Rodney E Wegner, Nissar Ahmed, Shaakir Hasan, Lana Y Schumacher, Athanasios Colonias","doi":"10.2217/lmt-2018-0012","DOIUrl":null,"url":null,"abstract":"Aim: Non-small-cell lung cancer recurs locally 10-40% of the time after local therapy, presenting a therapeutic challenge given poor pulmonary reserve. Herein, we seek to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) for retreatment of such patients.Methods: We identified and reviewed clinical outcomes in ten patients with recurrent non-small-cell lung cancer after past vicryl mesh brachytherapy.Results: Ten patients with a median age of 77 were treated to a median dose of 48 Gy in five fractions. Local control at 1 year was 88%. There was one distant failure at 29 months. There was no significant toxicity after SBRT.Conclusion: SBRT is safe and effective when used for re-irradiation after past ablative therapies.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2018-0012","citationCount":"1","resultStr":"{\"title\":\"Lung stereotactic body radiotherapy after past ablative therapy: a single institution case series.\",\"authors\":\"Rodney E Wegner, Nissar Ahmed, Shaakir Hasan, Lana Y Schumacher, Athanasios Colonias\",\"doi\":\"10.2217/lmt-2018-0012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: Non-small-cell lung cancer recurs locally 10-40% of the time after local therapy, presenting a therapeutic challenge given poor pulmonary reserve. Herein, we seek to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) for retreatment of such patients.Methods: We identified and reviewed clinical outcomes in ten patients with recurrent non-small-cell lung cancer after past vicryl mesh brachytherapy.Results: Ten patients with a median age of 77 were treated to a median dose of 48 Gy in five fractions. Local control at 1 year was 88%. There was one distant failure at 29 months. There was no significant toxicity after SBRT.Conclusion: SBRT is safe and effective when used for re-irradiation after past ablative therapies.\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2018-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/lmt-2018-0012\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/lmt-2018-0012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/11/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2018-0012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/11/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

目的:非小细胞肺癌在局部治疗后10-40%的时间局部复发，由于肺储备不良，对治疗提出了挑战。在此，我们试图评估立体定向放射治疗(SBRT)对此类患者再治疗的安全性和有效性。方法:我们确定并回顾了10例复发的非小细胞肺癌患者在过去的薇基网近距离治疗后的临床结果。结果:10例中位年龄为77岁的患者分5组接受中位剂量48 Gy的治疗。1年局部控制率为88%。在29个月的时候有一次遥远的失败。SBRT后无明显毒性反应。结论:SBRT用于既往消融治疗后的再照射是安全有效的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

Lung stereotactic body radiotherapy after past ablative therapy: a single institution case series.

Aim: Non-small-cell lung cancer recurs locally 10-40% of the time after local therapy, presenting a therapeutic challenge given poor pulmonary reserve. Herein, we seek to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) for retreatment of such patients.

Methods: We identified and reviewed clinical outcomes in ten patients with recurrent non-small-cell lung cancer after past vicryl mesh brachytherapy.

Results: Ten patients with a median age of 77 were treated to a median dose of 48 Gy in five fractions. Local control at 1 year was 88%. There was one distant failure at 29 months. There was no significant toxicity after SBRT.

Conclusion: SBRT is safe and effective when used for re-irradiation after past ablative therapies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助